KRTX

Karuna Therapeutics Inc

A biopharmaceutical company that developed KarXT, an oral medicine for schizophrenia and psychosis tied to Alzheimer's disease. The US FDA approved it in 2024 under the brand Cobenfy, marking the first new class of schizophrenia drugs in decades. Founded in Boston, the firm takes its name from the Sanskrit word "karuna," meaning compassion. Bristol Myers Squibb acquired it in 2024.